Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Summary
TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.
Official title: A Single-group, Open-label, Multicenter, Phase I Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
79
Start Date
2018-11-20
Completion Date
2023-03-17
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
TQ05105
TQ05105 is a JAK2 inhibitor.
Locations (2)
West China Hospital ,Sichuan University
Chengdu, Sichuan, China
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China